2. Academic Validation
  3. Characterization of β-d- N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus

Characterization of β-d- N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus

  • Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02395-16. doi: 10.1128/AAC.02395-16.
Maryam Ehteshami 1,  Sijia Tao 1,  Keivan Zandi 1 2,  Hui-Mien Hsiao 1,  Yong Jiang 1,  Emily Hammond 1,  Franck Amblard 1,  Olivia O Russell 1,  Andres Merits 3,  Raymond F Schinazi 4
Affiliations

Affiliations

  • 1 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • 2 Tropical Infectious Disease Research and Education Center (TIDREC), Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • 3 Institute of Technology, University of Tartu, Tartu, Estonia.
  • 4 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA [email protected].
PMID: 28137799 DOI: 10.1128/AAC.02395-16
Abstract

Chikungunya virus (CHIKV) represents a reemerging global threat to human health. Recent outbreaks across Asia, Europe, Africa, and the Caribbean have prompted renewed scientific interest in this mosquito-borne alphavirus. There are currently no vaccines against CHIKV, and treatment has been limited to nonspecific Antiviral agents, with suboptimal outcomes. Herein, we have identified β-d-N4-hydroxycytidine (NHC) as a novel inhibitor of CHIKV. NHC behaves as a pyrimidine ribonucleoside and selectively inhibits CHIKV replication in Cell Culture.

Keywords

Chikungunya virus; antiviral agents; nucleoside analogs; replicon.

Figures
Products